MiMedx Group Förvaltning
Förvaltning kriterier kontrolleras 2/4
MiMedx Group VD är Joe Capper, utsedd i Jan 2023, har en mandatperiod på 3.5 år. totala årliga ersättningen är $ 7.18M, bestående av 10.7% lön 89.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.21% av företagets aktier, värda $ 1.32M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 3.5 år respektive 5 år.
Viktig information
Joe Capper
Verkställande direktör
US$7.2m
Total ersättning
| VD-lön i procent | 10.70% |
| Anställning som VD | 3.5yrs |
| Ägande av VD | 0.2% |
| Ledningens genomsnittliga anställningstid | 3.5yrs |
| Styrelsens genomsnittliga mandatperiod | 5yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.
Uppdatering av berättelse • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Uppdatering av berättelse • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaUppdatering av berättelse • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Ny berättelse • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.Ny berättelse • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Uppdatering av berättelse • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Uppdatering av berättelse • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Uppdatering av berättelse • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Uppdatering av berättelse • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Uppdatering av berättelse • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Analysartikel • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Analysartikel • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Analysartikel • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analysartikel • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Analysartikel • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Ny berättelse • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$31m |
| Dec 31 2025 | US$7m | US$768k | US$49m |
| Sep 30 2025 | n/a | n/a | US$41m |
| Jun 30 2025 | n/a | n/a | US$32m |
| Mar 31 2025 | n/a | n/a | US$40m |
| Dec 31 2024 | US$1m | US$750k | US$42m |
| Sep 30 2024 | n/a | n/a | US$79m |
| Jun 30 2024 | n/a | n/a | US$79m |
| Mar 31 2024 | n/a | n/a | US$68m |
| Dec 31 2023 | US$21m | US$678k | US$56m |
Ersättning vs marknad: Joe s total kompensation ($USD 7.18M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 3.63M ).
Ersättning vs inkomst: Ersättningen för Joe har ökat med mer än 20 % medan företagets intäkter har minskat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Joe Capper (62 yo)
3.5yrs
Anställning
US$7,182,208
Kompensation
Mr. Joseph H. Capper, also known as Joe, is Independent Chairman of TELA Bio, Inc. from June 9, 2026. Mr. Capper is an Independent Director at Anika Therapeutics, Inc since May 28, 2024. He serves as Chief...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 3.5yrs | US$7.18m | 0.21% $ 1.3m | |
| Chief Financial Officer | 3yrs | US$2.12m | 0.15% $ 941.4k | |
| General Counsel & Chief Administrative Officer | 6.6yrs | US$2.15m | 0.24% $ 1.5m | |
| Chief Commercial Officer | 2.1yrs | US$2.06m | 0.021% $ 134.1k | |
| SVP of R&D & Medical Affairs and Chief Scientific Officer | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations | 3.8yrs | inga uppgifter | inga uppgifter | |
| Senior VP & Chief Compliance Officer | 3.3yrs | inga uppgifter | inga uppgifter | |
| Vice President of Investor Relations & Corporate Strategic Communications | no data | inga uppgifter | inga uppgifter | |
| Senior VP of Marketing & International | 3.4yrs | inga uppgifter | inga uppgifter | |
| Chief Human Resources Officer | less than a year | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | 7.6yrs | inga uppgifter | inga uppgifter | |
| President of Regenerative Medicine & Biologics Innovation | 5.9yrs | US$1.74m | inga uppgifter |
3.5yrs
Genomsnittlig anställningstid
60yo
Genomsnittlig ålder
Erfaren ledning: MDXG s ledningsgrupp anses vara erfaren ( 3.5 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 3.5yrs | US$7.18m | 0.21% $ 1.3m | |
| Independent Preferred Director | 6yrs | inga uppgifter | 0.00034% $ 2.2k | |
| Independent Director | 7.1yrs | US$237.72k | 0.14% $ 906.4k | |
| Independent Chairman of the Board | 6yrs | US$226.75k | 0.14% $ 869.1k | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Regenerative Medicine Scientific Advisory Board | 4yrs | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 7.1yrs | US$235.58k | 0.28% $ 1.8m | |
| Member of Regenerative Medicine Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Regenerative Medicine Scientific Advisory Board | 4yrs | inga uppgifter | inga uppgifter | |
| Member of Regenerative Medicine Scientific Advisory Board | 4yrs | inga uppgifter | inga uppgifter |
5.0yrs
Genomsnittlig anställningstid
71yo
Genomsnittlig ålder
Erfaren styrelse: MDXG s styrelse anses vara erfaren ( 5 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/28 22:45 |
| Aktiekurs vid dagens slut | 2026/07/28 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
MiMedx Group, Inc. bevakas av 10 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |